



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin Receives the 2014 ASTD BEST Award for Learning & Development

Mumbai, Baltimore, July 16, 2014: Pharma Major Lupin Limited (Lupin) announced today that the company has received the prestigious American Society for Training and Development (ASTD) BEST Award for Learning & Development for the year 2014. The award recognizes organizations that leverage the learning function as a strategic business tool to get results and which create, support, and champion learning opportunities to drive performance and build a learning culture.

Based at Washington DC, the American Society for Training and Development, now known as the Association for Talent Development is the World's best-known non-profit organization for propagating the Learning and Development function. Established in 2003, the BEST Awards Winner's Circle includes small and large, private, public companies and not-for-profit organizations from around the world.

Commenting on the award Rituraj Sar, Vice President, Learning & Development, Lupin Limited said; "Learning and development programs at Lupin are guided by an overarching philosophy of making a business impact with everything we do. To having made it to an elite list of companies who have won this award speaks volumes about the kind of rigor that has gone into learning and development initiatives at Lupin which are designed to ensure that they equip and empower Lupinytts with skills that improve productivity and efficiencies within the system. A clearly defined assessment approach captures the needs of the business and links it to individual performance; enabling learning and development programs to bridge the gap if any between the two"

Commenting on the Award, Mr. Nilesh Gupta, Managing Director, Lupin Limited said; "We are pleased to have won this award and make it to this prestigious list. This award bears testimony to Lupin's commitment towards our people, nurturing them to create a dynamic talent pool aligned with our values and vision, which will serve the current and future needs of our organization."

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364 million (USD 304 million) respectively. Please visit <http://www.lupinworld.com> for more information.

For more information, please contact -

Shamsher Gorawara

Head – Corporate Communications

Ph: +91- 98 20 338 555

Email: shamshergorawara@lupinpharma.com

[Safe Harbor Statement](#)